Pricing Log in Create free account

Adaptimmune Therapeutics PLC (ADAPY) vs MARKER THERAPEUTICS, INC. (MRKR)

Adaptimmune Therapeutics PLC and MARKER THERAPEUTICS, INC. are both Biotechnology companies. Adaptimmune Therapeutics PLC and MARKER THERAPEUTICS, INC. are of similar size ($14.9M and $14.6M). MARKER THERAPEUTICS, INC. grew revenue faster over the last twelve months: −46.2% against −54.0%. MARKER THERAPEUTICS, INC. has the higher net margin (0.00% vs −262.5%) and the lower return on invested capital (−566.8% vs 0.00%). Across the 17 metrics below, MARKER THERAPEUTICS, INC. leads on 10 and Adaptimmune Therapeutics PLC on 7.

Valuation

Metric ADAPY MRKR Biotechnology median
P/E n/m n/m 10.60
P/S 0.08 5.01 9.40
P/B n/m 1.46 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 0.08 1.88 9.02
Earnings yield (3,250.00%) (49.75%) (32.88%)
Free cash flow yield (3,648.13%) (123.23%) (23.13%)

Profitability

Metric ADAPY MRKR Biotechnology median
Gross margin 94.81% 134.12% 68.51%
Operating margin (427.75%) 0.00% 0.00%
Net margin (262.46%) 0.00% 0.00%
Free cash flow margin (294.49%) 0.00% 0.00%
Return on equity (1,349.52%) (76.87%) (51.96%)
Return on assets 0.00% (59.33%) (46.06%)
Return on invested capital 0.00% (566.75%) 0.00%

Growth

Metric ADAPY MRKR Biotechnology median
Revenue growth (TTM) (53.99%) (46.19%) 6.76%
EPS growth (last fiscal year) 142.86% 33.61% 29.88%
Revenue growth, 5-year CAGR 8.40% 50.02% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADAPY MRKR Biotechnology median
Debt to equity (0.36) 0.07 0.00
Current ratio 1.52 6.03 4.97
Net debt to EBITDA 0.47 1.32 1.01

Dividend

Metric ADAPY MRKR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ADAPY MRKR Biotechnology median
Market cap 14.55m 14.93m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack